Lily Llorens
Overview
Explore the profile of Lily Llorens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
469
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pahwa R, Fox S, Hauser R, Isaacson S, Lytle J, Johnson R, et al.
Front Neurol
. 2022 Nov;
13:846126.
PMID: 36341088
Background: The Unified Dyskinesia Rating Scale (UDysRS) evaluates dyskinesia in patients with Parkinson's disease (PD). A minimal clinically important change (MCIC)-the smallest change in a treatment outcome that a patient...
2.
Cohen J, Cameron M, Goldman M, Goodman A, Miller A, Rollins A, et al.
Mult Scler
. 2021 Aug;
28(5):817-830.
PMID: 34449295
Background: ADS-5102, a delayed-release, extended-release (DR/ER) amantadine, improved walking speed in MS in a Phase 2 trial. Objective: The aim of this study was to present primary results of a...
3.
Cohen J, Hunter S, Brown T, Gudesblatt M, Thrower B, Llorens L, et al.
Mult Scler
. 2018 Jan;
25(4):601-609.
PMID: 29368539
Background: Walking impairment causes disability and reduced quality of life in patients with multiple sclerosis (MS). Objective: Characterize the safety and efficacy of ADS-5102 (amantadine) extended release capsules, 274 mg...
4.
File Jr T, Eckburg P, Talbot G, Llorens L, Friedland H
Int J Antimicrob Agents
. 2017 Jun;
50(2):247-251.
PMID: 28599867
Background: Therapy directed against atypical pathogens in patients with community-acquired pneumonia (CAP) is often recommended. This post-hoc analysis evaluated the effect of addition of a macrolide to ceftaroline fosamil or...
5.
Powers 3rd J, Howard K, Saretsky T, Clifford S, Hoffmann S, Llorens L, et al.
Clin Infect Dis
. 2016 Aug;
63 Suppl 2:S52-6.
PMID: 27481954
The goal of administering medical interventions is to help patients live longer or live better. In keeping with this goal, there has been increasing interest in taking the "voice" of...
6.
Taboada M, Melnick D, Iaconis J, Sun F, Zhong N, File T, et al.
J Antimicrob Chemother
. 2016 Apr;
71(6):1748-9.
PMID: 27076104
No abstract available.
7.
Mazuski J, Gasink L, Armstrong J, Broadhurst H, Stone G, Rank D, et al.
Clin Infect Dis
. 2016 Mar;
62(11):1380-1389.
PMID: 26962078
Background: When combined with ceftazidime, the novel non-β-lactam β-lactamase inhibitor avibactam provides a carbapenem alternative against multidrug-resistant infections. Efficacy and safety of ceftazidime-avibactam plus metronidazole were compared with meropenem in...
8.
Taboada M, Melnick D, Iaconis J, Sun F, Zhong N, File T, et al.
J Antimicrob Chemother
. 2015 Dec;
71(4):862-70.
PMID: 26702925
Background: We conducted a meta-analysis of clinical trials of adults hospitalized with pneumonia outcomes research team (PORT) risk class 3-4 community-acquired pneumonia (CAP) receiving ceftaroline fosamil versus ceftriaxone. Methods: Three...
9.
Jandourek A, Smith A, Llorens L, Thye D, Eckburg P, Friedland H
Hosp Pract (1995)
. 2014 Feb;
42(1):75-8.
PMID: 24566599
Objectives: Few publications of prospective studies have described patient outcomes in community-acquired bacterial pneumonia (CABP)-associated bacteremia. Our objective, in performing this subgroup analysis, was to assess outcomes in subjects with...
10.
Riccobene T, Rekeda L, Rank D, Llorens L
Antimicrob Agents Chemother
. 2013 Jan;
57(4):1777-83.
PMID: 23357764
A randomized, double-blind, placebo-controlled, 3-period crossover study was conducted in 54 healthy adults to assess the effect of ceftaroline fosamil on the corrected QT (QTc) interval. The QT interval, corrected...